Off-label use of medications in children undergoing sedation and anesthesia

Anesthesia and Analgesia

Volumn 115, Issue 5, 2012, Pages 1148-1154

  Smith, Michael C ^a   Williamson, Julie ^b   Yaster, Myron ^a   Boyd, Geoffrey J C ^c   Heitmiller, Eugenie S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; DOPAMINE; HYDROMORPHONE; NEOSTIGMINE;

ANESTHESIA; ARTICLE; CHILD; DATA BASE; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; OFF LABEL DRUG USE; PEDIATRIC ANESTHESIA; PRIORITY JOURNAL; SEDATION;

ANESTHESIA; CHILD; DATABASES, FACTUAL; DRUG LABELING; HUMANS; HYPNOTICS AND SEDATIVES; OFF-LABEL USE; PHARMACEUTICAL PREPARATIONS;

EID: 84868194261     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3182501b04     Document Type: Article

References (26)

1. United States Public Law 105-115e Nov 21, 1997. Title 1 Improving Regulations of Drugs Sec. 101-131. Food and Drug Modernization Act of 1997 21 USC 301 note
2. Gorman RL. The march toward rational therapeutics in children. Pediatr Infect Dis J 2003;22:1119-23
3. Department of Health, Education, and Welfare, Food and Drug Administration. Prescription drug advertising; content and format for labeling of human prescription drugs. Fed Reg 44:21 CFR 201.57(f) (9)(iv). June 26, 1979:37433
4. Department of Health and Human Services, Food and Drug Administration. Specific requirements on content and format of labeling for human prescription drugs; revision of "Pediatric Use" subsection in the labeling. Fed Reg 59(No. 238). 21 CFR section 201.57(f)(9) December 13, 1994:64240-50
5. Department of Health and Human Services, Food and Drug Administration. Best Pharmaceuticals for Children Act. Public Law 107-109. January 4, 2002
6. Department of Health and Human Services, Food and Drug Administration. Pediatric Research Equity Act. Public Law 108- 155. December 16, 2003
7. Ward RM, Kauffman R. Future of pediatric therapeutics: reauthorization of BPCA and PREA. Clin Pharmacol Ther 2007;81:477-9
8. Yang CP, Veltri MA, Anton B, Yaster M, Berkowitz ID. Food and Drug Administration approval for medications used in the pediatric intensive care unit: a continuing conundrum. Pediatr Crit Care Med 2011;12:e195-9
9. Yoon EY, Davis MM, El-Essawi H, Cabana MD. FDA labeling status of pediatric medications. Clin Pediatr (Phila) 2006;45: 75-7
10. Doherty DR, Pascuet E, Ni A, Stewart P, Splinter W, Vaillancourt R. Off-label drug use in pediatric anesthesia and intensive care according to official and pediatric reference formularies. Can J Anaesth. 2010;57:1078-8
11. Tzortzopoulou A, Cepeda MS, Schumann R, Carr DB. Antifibirinolytic agents for reducing blood loss in scoliosis surgery in children. Cochrane Database Syst Rev 2008;3:CD006883
12. Chauhan S, Das SN, Bisoi A, Kale S, Kiran U. Comparison of epsilon aminocaproic acid and tranexamic acid in pediatric cardiac surgery. J Cardiothorac Vasc Anesth 2004;18:141-3
13. Kenyon CA, Flick R, Moir C, Ackerman MJ, Pabelick CM. Anesthesia for videoscopic left cardiac sympathetic denervation in children with congenital long QT syndrome and catecholaminergic polymorphic ventricular tachycardia - a case series. Pediatr Anesth 2010;20:465-70
14. Tobin Jr. Use of pharmaceuticals 'off-label' in the neonate. Best Pract Res Clin Anaesthesiol 2010;24:451-60
15. Davidson AJ. Anesthesia and neurotoxicity to the developing brain: the clinical relevance. Paediatr Anaesth 2011;21:716-21
16. Department of Health and Human Services, Food and Drug Administration. Title 21 Code of Federal Regulation, April 1, 2011. Part 201, §201.57
17. Tobin JR, Shafer SL, Davis P. Pediatric research and scholarship: another Gordian Knot. Anesth Analg. 2006;103(1):43-8
18. Mason J, Pirmohamed M, Nunn T. Off-label and unlicensed medicine use and adverse drug reactions in children: a narrative review of the literature. Eur J Clin Pharmacol 2011 Jul 22. Epub ahead of print
19. Rajchert DM, Pasquariello CA, Watcha MF, Schreiner MS. Rapacuronium and the risk of bronchospams in pediatric patients. Anesth Analg. 2002;94(3):488-93
20. Pub. L. No. 75-717, § 201(g)(1)(B), ch. 675, 52 Stat. 1040 (June 25, 1938) (as amended 1962) (codified as amended at 21 U.S.C. § 321(g)(1)(B))
21. Fed. Reg. 19,466 (1987) (codified at 21 C.F.R. § 312 (1993).
22. Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products. Fed Reg. 2006;71(15):3922-3997
23. FDA, Legal Status of Approved Labeling of Prescription Drugs; Prescribing for Uses Unapproved by the FDA, 37 Fed. Reg. 16503, 16503; Aug. 15, 1972
24. Henry V. Off-label prescribing. Legal implications. J Leg Med 1999;20:365-83
25. Cohen PJ. 'Off-label' use of prescription drugs: legal, clinical and policy considerations. Eur J Anesthesiol 1997;14:231-5
26. Hill P. Off license and off label prescribing in children: litigation fears for physicians. Arch Dis Child 2005;90(Suppl I):i17-8